https://pharmatlas.org/ 2026-04-06T05:51:27+00:00 https://pharmatlas.org/ https://pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-13T17:12:31+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:adenosine&rev=1771002751&do=diff Adenosine (Adenocard®, Adenoscan®) Drug Overview Class Antiarrhythmics Subclass Miscellaneous (AV Nodal Suppressant) Primary Use Paroxysmal SVT Route IV rapid bolus Onset Seconds Duration < 10 seconds Half-life ~10 seconds Metabolism Rapid uptake by RBCs & vascular endothelium text/html 2026-02-12T23:51:02+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:amiodarone&rev=1770940262&do=diff Amiodarone Amiodarone is a Class III antiarrhythmic with multi-class electrophysiologic effects. It blocks: • Potassium channels (Class III) • Sodium channels (Class I) • Beta receptors (Class II) • Calcium channels (Class IV) Because of this broad activity, amiodarone is highly effective for both atrial and ventricular arrhythmias. text/html 2026-02-13T17:16:58+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:atropine&rev=1771003018&do=diff Atropine (Atropen®, Isopto Atropine®) Drug Overview Drug Class Antimuscarinics Subclass Competitive Muscarinic Antagonist Primary CV Use Symptomatic Bradycardia Route IV / IM / SQ / Ophthalmic Onset (IV) 1–2 minutes Duration 30–60 minutes Half-life ~2–4 hours Metabolism Hepatic text/html 2026-02-13T17:18:20+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:bradycardia&rev=1771003100&do=diff Bradycardia Algorithm Bradycardia is defined as: * Heart rate < 60 bpm Clinical relevance depends on: * Symptoms * Hemodynamic stability * Presence of AV block This page follows the Dysrhythmias Module and mirrors ACLS principles. ---------- Step 1 – Identify Symptomatic vs Asymptomatic text/html 2026-02-13T17:19:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:digoxin&rev=1771003187&do=diff Digoxin (Lanoxin®) Drug Overview Drug Class Cardiac Glycoside Subclass Na⁺/K⁺ ATPase Inhibitor Primary Uses HFrEF; Atrial Fibrillation Route Oral / IV Onset (IV) 5–30 minutes Half-life ~36–48 hours (normal renal function) Metabolism Minimal hepatic Elimination Renal text/html 2026-02-12T23:51:54+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:dofetilide&rev=1770940314&do=diff Dofetilide Dofetilide is a pure Class III antiarrhythmic that blocks cardiac potassium channels. It prolongs repolarization and increases refractory period without significant sodium, beta, or calcium channel effects. → Dysrhythmias Module ---------- Mechanism of Action text/html 2026-02-15T03:15:09+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:dronedarone&rev=1771125309&do=diff Dronedarone (Multaq®) Dronedarone Brand Name Multaq® Drug Class Class III Antiarrhythmic Vaughan-Williams Class Class III (Multichannel Blocker) Primary Indication Atrial Fibrillation / Atrial Flutter QT Prolongation Yes Iodine Content No Half-Life ~24 hours text/html 2026-02-13T17:13:39+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:arrhythmias:start&rev=1771002819&do=diff Module 7 – Cardiac Electrophysiology & Dysrhythmias Dysrhythmias result from abnormalities in: • Automaticity • Triggered activity • Conduction Successful treatment requires understanding the cardiac action potential. ---------- Cardiac Action Potentials